RxDoctor Payments Data

Nicole Bales

Nurse Practitioner · Grimes, IANPI 1164155040

Payments from drug & device makers

$1,353in general payments, 2019–2025

Across 48 payments — averaging $28.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$429
  • AstraZeneca$314
  • Heartflow, Inc.$150
  • Fresenius USA Marketing, Inc.$125
  • Abbott$96
  • Boehringer Ingelheim$86
  • plus $153 from 8 others

What the payments were for

  • Food & beverage$1,25393%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,353 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$4,056
Medicare patients
43
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$13,970
JardianceEmpagliflozin17$9,897
EntrestoSacubitril/Valsartan19$9,574
BrilintaTicagrelor19$8,418
Metoprolol Succinate31$267
Isosorbide Mononitrate ErIsosorbide Mononitrate16$174
Nitroglycerin23$151
Atorvastatin Calcium38$130
Carvedilol37$113
ClopidogrelClopidogrel Bisulfate22$88
Hydralazine Hcl13$85
Spironolactone24$64
Losartan Potassium19$61
Lisinopril26$56
Amlodipine Besylate26$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$86$9,89717 claims
AstraZenecaBrilinta$314$8,41819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Grimes

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →